Note from Steven Lane, President HSANZ

The TGA has recently approved EVUSHELD, a novel combination of two antibodies that target the SARS-CoV-2 virus, to be used to prevent the development of COVID in patients with moderate to severe immune deficiency. We understand that stocks will be limited and that EVUSHELD will be distributed through statewide cancer networks in the first instance. This represents a major breakthrough for patients who are unable to mount adequate vaccine responses including patients post-stem cell transplantation, or who have had b-cell depleting therapies. A joint HSANZ position statement is under development.

https://www.tga.gov.au/tga-provisionally-approves-astrazenecas-combination-therapy-tixagevimab-and-cilgavimab-evusheld-pre-exposure-prevention-prophylaxis-covid-19